Table 2.

Clinical characteristics of the SA group before and after SSA treatment.

	SA group (n = 63)
Baseline GH, μg/L	40.9 (15.7–56.1)
Post-SSA GH, μg/L	7.9 (2.9–34.6)
% GH reduction	69.6 (32.4–90.5)
Baseline IGF-1 index	3.0 (2.6–3.6)
Post-SSA IGF-1 index	2.0 (1.3–2.5)
% IGF-1 index reduction	34.0 (12.6–54.3)
% tumor reduction	23 (10–45)

SA, pretreatment with somatostatin analogues before surgery; GH, growth hormone; IGF-1, insulin-like growth factor 1; SSA, somatostatin analogues. Data are median with interquartile range.